These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 3913618

  • 1. [Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA) in humans].
    Zucca E, Cattaneo MT, Cavalli F, Guaitani A, Filipazzi V, Bartosek I.
    G Ital Chemioter; 1985; 32(1):25-8. PubMed ID: 3913618
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.
    Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR.
    Cancer Res; 1984 Apr; 44(4):1693-7. PubMed ID: 6367971
    [Abstract] [Full Text] [Related]

  • 3. Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
    Sharma H, Thatcher N, Baer J, Zaki A, Smith A, McAucliffe CA, Crowther D, Owens S, Fox BW.
    Cancer Chemother Pharmacol; 1983 Apr; 11(1):5-7. PubMed ID: 6349844
    [Abstract] [Full Text] [Related]

  • 4. [Results of a phase-I clinical study of carboplatin--(cyclobutane-1,1-dicarboxylate)diamineplatinum (II)].
    Gorbunova VA.
    Vestn Akad Med Nauk SSSR; 1986 Apr; (5):45-7. PubMed ID: 3524054
    [No Abstract] [Full Text] [Related]

  • 5. Hyperthermic enhancement of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) cytotoxicity in human leukemia cells in vitro.
    Cohen JD, Robins HI.
    Cancer Res; 1987 Aug 15; 47(16):4335-7. PubMed ID: 3300964
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
    Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J.
    Cancer Res; 1984 Nov 15; 44(11):5432-8. PubMed ID: 6386150
    [Abstract] [Full Text] [Related]

  • 7. Interactions of thymidine, hyperthermia, and cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in human T-cell leukemia.
    Cohen JD, Robins HI, Schmitt CL, Tanner MA.
    Cancer Res; 1989 Nov 01; 49(21):5805-9. PubMed ID: 2676150
    [Abstract] [Full Text] [Related]

  • 8. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.
    Van Echo DA, Egorin MJ, Whitacre MY, Olman EA, Aisner J.
    Cancer Treat Rep; 1984 Sep 01; 68(9):1103-14. PubMed ID: 6383605
    [Abstract] [Full Text] [Related]

  • 9. Antitumor effect of carboplatin combined with hyperthermia on Ehrlich-ascites tumor in vivo.
    Mizuuchi H, Yoshiga K, Sakurai K, Tsumura M, Takada K.
    Anticancer Res; 1996 Sep 01; 16(1):381-7. PubMed ID: 8615640
    [Abstract] [Full Text] [Related]

  • 10. A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240).
    Curt GA, Grygiel JJ, Corden BJ, Ozols RF, Weiss RB, Tell DT, Myers CE, Collins JM.
    Cancer Res; 1983 Sep 01; 43(9):4470-3. PubMed ID: 6347373
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
    Brouwers EE, Tibben MM, Rosing H, Hillebrand MJ, Joerger M, Schellens JH, Beijnen JH.
    J Mass Spectrom; 2006 Sep 01; 41(9):1186-94. PubMed ID: 16929560
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S.
    Ota K, Oguma T, Shimamura K.
    Anticancer Res; 1994 Sep 01; 14(3B):1383-7. PubMed ID: 8067710
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and anticancer activity of [2-hydroxy-1,3-diaminopropane-kappa 2N,N'] platinum(II) complexes.
    Liu W, Chen X, Xie M, Lou L, Ye Q, Yu Y, Hou S.
    J Inorg Biochem; 2008 Oct 01; 102(10):1942-6. PubMed ID: 18707762
    [Abstract] [Full Text] [Related]

  • 15. [Platinum derivatives].
    Sasaki Y.
    Nihon Rinsho; 1999 Sep 01; 57 Suppl():425-7. PubMed ID: 10543144
    [No Abstract] [Full Text] [Related]

  • 16. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
    Joss RA, Kaplan S, Goldhirsch A, Sessa C, Brunner KW, Cavalli F.
    Invest New Drugs; 1984 Sep 01; 2(3):297-304. PubMed ID: 6392147
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of (glycolate-0,0')-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin.
    Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S.
    Cancer Chemother Pharmacol; 1989 Sep 01; 23(4):243-6. PubMed ID: 2647312
    [Abstract] [Full Text] [Related]

  • 18. Experimental studies on the pharmacokinetics and nephrotoxicity of carboplatin (cis-diammine-1, 1-cyclobutane dicarboxylate platinum II) in rats.
    Ueda T, Yasumasu T, Uozumi J.
    J Toxicol Sci; 1991 Aug 01; 16(3):101-9. PubMed ID: 1942134
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Study on nephrotoxicity in rats receiving cis-diammine-1,1-cyclobutane dicarboxylate platinum II--special reference to morphological changes].
    Kimura S, Nakajima Y, Hasegawa S, Tazaki H.
    Nihon Hinyokika Gakkai Zasshi; 1989 Apr 01; 80(4):517-25. PubMed ID: 2664296
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.